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ABSTRACT
Women with epithelial ovarian cancer (EOC) are usually treated with platinum/
taxane therapy after cytoreductive surgery but there is considerable inter-individual 
variation in response. To identify germline single-nucleotide polymorphisms 
(SNPs) that contribute to variations in individual responses to chemotherapy, we 
carried out a multi-phase genome-wide association study (GWAS) in 1,244 women 
diagnosed with serous EOC who were treated with the same first-line chemotherapy, 
carboplatin and paclitaxel. We identified two SNPs (rs7874043 and rs72700653) in 
TTC39B (best P=7x10-5, HR=1.90, for rs7874043) associated with progression-free 
survival (PFS). Functional analyses show that both SNPs lie in a putative regulatory 
element (PRE) that physically interacts with the promoters of PSIP1, CCDC171 and 
an alternative promoter of TTC39B. The C allele of rs7874043 is associated with poor 
PFS and showed increased binding of the Sp1 transcription factor, which is critical 
for chromatin interactions with PSIP1. Silencing of PSIP1 significantly impaired 
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INTRODUCTION
Ovarian cancer is the fifth leading cause of cancer 
deaths among women worldwide with an estimated 
225,500 new cases annually [1]. Although ovarian cancer 
is among the most chemo-sensitive of solid tumors and 
generally shows a good initial response to platinum/taxane 
treatment and optimal debulking surgery, the disease will 
recur in 60-80% of women with advanced disease within 
five years [2, 3]. Considerable effort has been focused on 
identifying predictors of outcome at the somatic level, 
but less emphasis has been placed on the identification 
of germline predictors of outcome. We and others have 
used the candidate gene approach to identify ATP-
binding cassette family members that might be associated 
with PFS [4, 5]. However, these findings have not been 
convincingly validated [5, 6].
Genome-wide association studies (GWAS) have 
been extremely successful at finding susceptibility loci 
for many different complex diseases [7], including 
multiple cancers [8]. The successful identification of 
loci associated with response to treatment could have 
profound clinical implications for individualizing anti-
cancer treatment but there have been very few successful 
GWAS identifying loci associated with outcome for any 
cancer [9-16]. One factor that might explain this is that 
for most cancers there is considerable heterogeneity in 
the chemotherapeutic regimens used, which is likely to 
contribute to heterogeneity in treatment response [17-19]. 
In addition, it has been difficult to compile germline DNA 
and detailed treatment and clinical follow-up information 
on a sufficiently large number of patients to provide 
enough statistical power to detect loci associated with PFS 
or overall survival (OS).
In this study, we aimed to identify germline 
polymorphisms that influence response to first-line 
chemotherapy in patients with EOC. Based on previous 
ex vivo studies in lymphoblastoid cell lines derived from 
related family members that have shown moderately high 
heritability (0.21 to 0.7, depending on dose) for sensitivity 
to docetaxel [20] and cisplatin-induced cytotoxicity [21], 
we hypothesized that inter-patient variability in response 
to these drugs may be in part be explained by genetic 
variation that could be identified if we used a cohort of 
patients who had been uniformly treated. Therefore, we 
conducted the GWAS of PFS in ovarian cancer patients 
treated with carboplatin and paclitaxel, with the initial 
GWAS on 385 patients with high-grade, serous cancer 
(HGSC) and follow-up phases on serous EOC patients 
from ten studies from the Ovarian Cancer Association 
Consortium (OCAC). 
We identified two rare SNPs that fall within 
a regulatory element within intron 2 of TTC39B. 
Chromatin conformation assays showed that the targets 
of the regulatory element are PSIP1, CCDC171 and an 
alternative promoter of TTC39B. DNA-protein analyses 
indicated that the likely functional SNP is rs7874043, 
which alters Sp1 transcription factor binding, a factor that 
is critical for chromatin looping between the PRE and the 
PSIP1 promoter. Furthermore, we show that silencing 
of PSIP1 significantly impaired DNA damage-induced 
homologous recombination function in ovarian cancer cell 
lines. According to KM-plotter (an online database linking 
expression to ovarian outcome in publicly available data), 
high expression of PSIP1 is associated with poor PFS in 
ovarian cancer suggesting that altered PSIP1 expression 
may be driving the association between the associated 
SNPs and outcome in EOC patients [22]. 
RESULTS
Four-phase GWAS
We carried out a four-phase genome-wide 
association study of PFS in a total of 1,244 serous ovarian 
cancer patients who had debulking surgery and were 
uniformly treated with only carboplatin and paclitaxel as 
first-line therapy (Figure 1). 
In Phase 1, we conducted a genome-wide scan on 
germline DNA from 385 patients from the Australian 
Ovarian Cancer Study (AOCS, n = 183), the Mayo Clinic 
(MAYO, n = 68) and The Cancer Genome Atlas (TCGA, 
n = 134) and performed a meta-analysis summarizing 
results from these cohorts (refer to Methods for details of 
genotyping and imputation). The Manhattan plot showing 
SNP association with PFS is presented in Supplementary 
Figure 1. We then prioritized 190 SNPs primarily ranked 
by P-value in Phase 1 for validation and further replication 
(Supplementary Table 1). We also included 10 SNPs in 
the gene YAP1, in light of its association with response 
to platinum-based chemotherapy in small-cell lung cancer 
patients [14], to test whether this finding would replicate 
in our study. These SNPs were also genotyped on Phase 
1 AOCS and MAYO samples (DNA samples were not 
available for TCGA) so that we could replace imputed 
data with actual genotypes for these samples in subsequent 
analyses.
In Phase 2, we genotyped these 200 SNPs in 706 
DNA damage-induced Rad51 nuclear foci and reduced cell viability in ovarian cancer 
lines. PSIP1 (PC4 and SFRS1 Interacting Protein 1) is known to protect cells from 
stress-induced apoptosis, and high expression is associated with poor PFS in EOC 
patients. We therefore suggest that the minor allele of rs7874043 confers poor PFS 
by increasing PSIP1 expression.
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patients from 8 studies participating in OCAC. Following 
further data cleaning, we updated treatment details and 
other clinical information prior to Phase 2 analysis, which 
revealed 106 patients included in the Phase 1 GWAS who 
were no longer eligible for inclusion mainly due to the 
fact that these patients received additional agents or did 
not meet the dose requirement (Methods). Therefore, we 
performed a pooled analysis of 985 patients from both 
phases with these 106 patients excluded. This analysis 
identified two uncommon SNPs in strong linkage 
disequilibrium (LD), rs72700653 and rs7874043 (minor 
allele frequency (MAF) ~ 1.85% and imputation r2 = 0.9) 
in intron 2 of TTC39B, most strongly associated with 
PFS in serous ovarian cancer patients (P = 3.5x10-7 and 
3.6x10-7 for rs72700653 and rs7874043 respectively; 
Supplementary Table 1). Both SNPs were imputed with 
high quality (imputation quality score r2 = 0.81 in MACH 
[23]). None of the 10 tag SNPs in the YAP1 gene were 
associated with PFS in these 985 patients (P > 0.05, 
Supplementary Table 1). 
In Phase 3, we genotyped 38 tagSNPs, in addition 
to rs72700653 and rs7874043, in 985 OCAC samples to 
perform fine-mapping of the TTC39B locus. rs7874043 
and rs72700653 remained the SNPs most associated 
with PFS at this locus, and the variants in moderate LD 
with rs7874043 showed consistent association with PFS 
(Supplementary Table 2). In Phase 4, we sought further 
replication of the association between these two variants 
and PFS in two additional cohorts, MAC (n = 26) and the 
clinical trial, ICON7 (n = 124) and additional samples 
from OCAC (n = 109). As there were only a small number 
of eligible cases in MAC, and both MAC and MAYO 
studies were recruited at the Mayo Clinic, we combined 
these two sets for analysis. 
To get an overall estimate of the hazard ratio, we 
pooled all available data from Phase 1, 2 (again excluding 
the ineligible patients) and 4 (n = 1244). Details of 
all the OCAC sites contributing to this study are given 
in Supplementary Table 3. This analysis showed that 
the minor allele of rs7874043 was associated with 
significantly worse PFS (HR = 1.90, 95% CI = 1.38 to 
2.61, P = 7.3x10-5; Figure 2a). The median PFS in patients 
homozygous for the common allele of rs7874043 was 16.0 
months (95% CI = 15.0 to 17.1), compared to 11.5 months 
(95% CI = 9.5 to 15.4) in heterozygous patients, without 
adjustment for covariates (log-rank test P = 0.0098); 
while the difference was 17.2 months (95% CI = 16 to 
18.1) versus 11.5 months (95% CI = 9.6 to 14.7) when we 
assumed all prognostic factors at their mean values (Figure 
2b, Supplementary Figure 2). The result of association 
between this SNP and PFS was similar when restricted to 
the high-grade serous patients at advanced disease stage (n 
= 1061, HR = 1.86, 95% CI = 1.33 to 2.6, P = 2.6x10-4). 
The median PFS was 14.8 months (95% CI = 14 to 15.8) 
for these patients with homozygous genotypes versus 11.0 
months (95% CI = 9.3 to 14.1) for heterozygote patients, 
assuming mean covariates. The other SNP in high LD, 
rs72700653, despite a similar HR, had weaker association 
than rs7874043 due to more missing genotypes (HR = 
1.91, 95% CI = 1.36 to 2.69, P = 2.2x10-4). We found 
attenuated associations with PFS in OCAC patients who 
were selected with no regard to chemotherapy (HR = 1.31, 
Figure 1: Study Design. Overview of the study design for the identification of TTC39B SNPs using a four-phase GWAS of PFS in 
serous EOC patients. 
Oncotarget6357www.impactjournals.com/oncotarget
Figure 2: Association with PFS in serous EOC patients. A. Associations between the TTC39B SNP rs7874043 and PFS in 
individual studies (rows denoted by study names), and the overall association pooling all samples together while stratifying for studies 
(the row denoted by “Pooled”). “HR” indicates the point estimates of hazard ratio. “L95” and “H95” represents its lower and upper 95% 
confidence intervals. “NA” indicates no minor allele was found in the eligible cases. The forest plot on the right is on the log scale. B. 
Baseline survival curves of the two genotypes (AA vs AC) of rs7874043 in a stratified Cox regression, assuming all other prognostic factors 
at mean values. Patients with CC genotypes were not observed due to the low minor allele frequency of rs7874043. The survival curves 
were truncated at 80 months as only a few events occurred after that. 
Figure 3: Chromatin structure and DNA-protein interactions surrounding the 9p22 PFS-associated SNPs. A. Colored 
histograms denote histone modification ChIP-seq data from UCSD and ENCODE. Epigenetic marks for H3K4me1 and H3K27ac in ovary 
from UCSD and 7 cell types from ENCODE, and transcription factor ChIP-seq data from ENCODE are shown. The grey shaded region 
denotes the PRE containing SNPs rs72700653 and rs7874043. B. EMSA for oligonucleotides containing SNP rs7874043 with the A = 
common allele and C = minor allele as indicated below the panel, assayed using JAM and A2780 nuclear extracts. Labels above each lane 
indicate inclusion of competitor oligonucleotides at 30-fold molar excess: (-) no competitor (Lanes 1,2,8,9); Self-C allele (Lanes 3,10), 
AP1 (Lanes 4,11), FOXA1 (Lanes 5,12), Sp1 (Lanes 6,13) and a control sequence (Lanes 7,14; containing binding site for ATF, a TF not 
predicted to bind). The Sp1-containing complexes are indicated with red arrowheads. C. ChIP-qPCR on the PRE in JAM and A2780 cell 
lines. ChIP assays were performed with Sp1 antibodies or non-immune IgG, with a region 2.3kb upstream of the predicted Sp1-binding site 
(Control) used as a control for nonspecific binding. Graphs represent two biological replicates. Error bars denote SD.
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95% CI = 1.04 to 1.66, P = 0.02; Supplementary Figure 3),
We also determined whether TTC39B SNPs were 
associated with OS. rs7874043 showed a significant, but 
weaker association with OS. The minor allele was also 
associated with worse OS (HR = 1.56, 95% CI = 1.09 to 
2.23, P = 0.015). The median OS differences unadjusted 
for covariates were 46.3 months (95% CI = 43.2 to 49.9) 
for patients with homozygous genotypes versus 37 months 
(95% CI = 29.8 to 53.8) for heterozygous patients (log-
rank test P = 0.048), and 48.7 months (95% CI = 45.4 
to 55.3) versus 38.9 months (95% CI = 29.8 to 55.5) 
assuming mean covariates (Supplementary Figure 4). 
PFS-associated SNPs fall within a distal 
regulatory element of PSIP1, CCDC171 and an 
alternative promoter of TTC39B
Regulatory elements such as promoters and 
transcriptional enhancers/silencers can be identified by 
distinct chromatin marks. Tri-methylation of histone 
3 lysine 4 (H3K4Me3) marks promoters, while mono-
methylation (H3K3Me1) marks promoters and enhancers. 
ENCODE ChIP-seq data for H3K4Me1 from eight 
different cell lines covering the TTC39B locus revealed 
that both rs7874043 and rs72700653 fall within a putative 
regulatory element (PRE) marked by H3K4Me1 within 
intron 2 of TTC39B (Figure 3a). Transcription factor 
binding prediction indicated potential SNP-altered 
binding of Sp1, FOXA1 and AP1 (Supplementary Figure 
5; [24]). We performed electrophoretic mobility shift 
assays (EMSAs) to assess binding of these transcription 
factors to the common and minor alleles of each of these 
variants and showed allele-specific protein binding 
for rs7874043 (Figure 3b; lanes 1, 2 and 8, 9). EMSAs 
using an Sp1 consensus oligonucleotide as competitor 
suggested that a strong higher mobility band and a weaker 
lower mobility band (in JAMs only) is likely to be Sp1 
(Figure 3b, Supplementary Figure 6a). Using chromatin 
immunoprecipitation experiments we have shown that Sp1 
is able to bind this site in JAM and A2780 ovarian cancer 
cell lines in vivo (Figure 3c). We also observed protein 
interaction at rs72700653, but found no difference in 
binding between alleles (Supplementary Figure 6b).
Figure 4: Chromatin interactions at 9p22 in ovarian cancer cell lines. A. Physical map spanning 2Mb of the 9p22 region 
showing the position of all annotated genes assessed by 3C. The red arrowhead denotes TTC39B. B.-D. 3C interaction profiles between 
the PRE (containing rs72700653 and rs7874043) and (B) TTC39B, (C) PSIP1 and (D) CCDC171 promoter regions. 3C libraries were 
generated with either HindIII (B) or EcoRI (C and D), with the anchor point set at the PRE. A physical map of the region interrogated by 
3C and relevant ENCODE histone modification data is shown above. A representative graph of three biological replicates is shown. Error 
bars denote SD. 
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To determine the likely target genes of the PRE, 
we performed chromosome conformation capture (3C) 
using an anchor primer within the restriction fragment 
encompassing the PRE and a series of primers within 
restriction fragments spanning all protein coding gene 
promoters within two megabases of the PRE (Figure 4a). 
The results showed that the PRE frequently interacts with 
an alternative (1B) promoter of TTC39B in both A2780 and 
JAM cells (Figure 4b). The PRE also frequently interacted 
with the PSIP1 (also known as LEDGF) promoter, located 
approximately 260kb away, in JAM but not A2780 cells, 
and the CCDC171 promoter, approximately 300kb 
away, in both JAM and A2780 cells (Figure 4c and 4d; 
Supplementary Figure 7). All chromatin interactions 
were confirmed by performing 3C with an independent 
restriction enzyme using anchor primers in the relevant 
gene promoters and a series of primers spanning the PRE 
(Supplementary Figure 8). No significant interactions 
were detected between the PRE and other flanking genes 
including NFIB, ZDHHC21, CER1, FREM1 or SNAPC3 
(Supplementary Figure 9).
Using luciferase reporter assays we demonstrated 
that the PRE acts as a strong transcriptional enhancer 
on the PSIP1 and CCDC171 promoters (Figure 5). 
Interestingly, the PRE had no significant effect on the 
TTC39B 1B promoter in A2780 cells and acted as a 
silencer in JAM cells suggesting that, depending on the 
cellular context, the PRE can act as an enhancer or silencer. 
To examine the effect of the SNPs on the activity of the 
PRE, we generated reporter constructs containing the 
minor alleles of both rs7874043 and rs72700653 (Figure 
5, TTC PRE HAP). In A2780 cells, inclusion of the PRE-
minor alleles significantly increased TTC39B 1B promoter 
activity and in JAM cells the minor alleles ablated the 
Figure 5: Evaluation of the function of rs72700653 and rs7874043 in ovarian cancer cell lines. A. Luciferase assays 
comparing effect of minor alleles on the function of TTC39B, PSIP1 and CCDC171 promoters. The PRE was cloned upstream of TTC39B, 
PSIP1 or CCDC171 promoter-driven luciferase reporter constructs with rs72700653 and rs7874043 (PRE HAP) or without (PRE WT). 
A2780 or JAM ovarian cancer cells were transiently transfected with each construct and assayed for luciferase activity after 24h. Error 
bars denote SEM (N  =  3). P values were determined with a two-tailed t test. *p  <  0.05, **p  <  0.01,***p  <  0.001. Effect of siRNA 
knock-down of SP1 on 3-C interactions between the PRE with B. PSIP1 and C. CCDC171 promoter regions in JAM cells. 3C libraries 
were generated with EcoRI, with the anchor point set at the PRE. A physical map of the region interrogated by 3C data is shown above. 
A representative graph of three biological replicates is shown. Error bars denote SD. D. Effect of siRNA knock-down on gene expression 
levels of PSIP and CCDC171 in JAM cells. JAM cells were transiently transfected using Sp1 (siSp1) RNAi smartpools or nontargeting 
control (siCON) and assayed after 48 hours. Gene expression was measured by TaqMan and is given relative to B-glucuronidase. Error 
bars denote SEM (N  =  3). P values were determined with a two-tailed t test. ****p  <  0.0001.
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PREs silencer activity. In both cell lines, inclusion of the 
PRE-minor alleles had no additional effect on PSIP1 and 
CCDC171 promoter activity. While this appears to rule 
out a direct effect of these SNPs on transactivation of 
these promoters, Sp1 is reported to regulate chromatin 
looping and therefore the SNPs may be influencing the 
physical interactions between the PRE and target genes 
[25]. To address this question, we performed 3C analysis 
on JAM cells after Sp1 siRNA-mediated silencing and 
showed that the chromatin interaction between the PRE 
and PSIP1 but not CCDC171 was ablated (Figure 5b and 
5c; Supplementary Figure 10). Consistent with this, the 
expression of PSIP1, but not CCDC171, decreased with 
Sp1 knockdown (Figure 5d). 
High expression of PSIP1 and CCDC171 is 
associated with PFS
We used Rapid Amplification of cDNA ends 
(RACE) to identify the transcript initiated from the 1B 
promoter of TTC39B, as there was none described. We 
identified a novel first exon of TTC39B, located ~13 kb 
downstream of the canonical exon 1, with a successive 
exon structure similar to the published TTC39B-202 
(Supplementary Figure 11a). Negligible expression 
of this novel transcript was found in 18 ovarian cancer 
cell lines, whilst in 149 serous ovarian epithelial tumors 
from the AOCS low or minimal expression was observed 
(Supplementary Figure 11b and 11c). There was no 
association between expression of this transcript and PFS 
(HR = 0.7 (95% CI 0.38 - 1.25); P = 0.21 for the upper 
decile vs remaining patients); nor were expression levels 
associated with rs7874043 genotype (P = 0.22), but there 
were only six heterozygous carriers among the 142 tumors 
analyzed (Supplementary Figure 11c). However, analysis 
of 1171 epithelial ovarian tumors in KM-plotter [22], the 
online tool for survival-associated biomarkers, showed a 
strong association between high PSIP1 expression and 
shorter PFS (Figure 6; HR = 1.44 (95% CI 1.23 - 1.68; 
P  =  6.6 x 10-6 for comparison above and below median 
PSIP1 expression). Since there were no data available 
in KM-plotter for CCDC171, we used the more limited 
TCGA serous ovarian cancer dataset and found that among 
the 68 patients with nil residual disease, high levels of 
CCDC171 were associated with PFS (Supplementary 
Figure 12; HR 5.04 (95% CI 1.99 - 12.79); P  =  0.001 
for the upper decile vs remaining patients). However, this 
was not evident among 374 patients with any debulking 
status (HR 1.25 (95% CI 0.84 - 1.86); P  =  0.266 for the 
upper decile vs remaining patients). In the TCGA dataset, 
expression of PSIP1 was positively correlated with that 
of CCDC171 and many other genes on the short arm of 
chromosome 9 (Supplementary Table 4). This appears to 
be largely because of co-amplification, as the correlations 
dropped noticeably upon correction for copy number.
PSIP1 is required for RAD51 foci formation after 
DNA damage in ovarian cancer cell lines
PSIP1 is known to facilitate the resection step 
during homologous recombination mediated-repair and is 
required for RAD51 foci formation after DNA damage in 
Figure 6: Kaplan-Meier curves of association between expression of PSIP1 with PFS in EOC. Expression of PSIP1 
(Affymetrix probe 205961_s_at; log rank P  =  6.6 x 10-6) and PFS in 1171 patients with serous and endometrioid EOC using the online tool 
KM-plotter [22]. High and low expression are defined as above and below the median.
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a number of cancer cell lines [26]. Therefore, to assess 
this function in ovarian cancer we silenced PSIP1 using 
siRNA in two high grade serous ovarian cancer cell lines, 
OVCAR3 and FUOV1 [27], which express relatively high 
levels of PSIP1 (Supplementary Figure. 13a and 13b). We 
observed a significant reduction in DNA damage-induced 
Rad51 foci formation in both cell lines. Representative 
images and quantification are shown for OVCAR3 using 
two independent siRNA sequences (Figure 7a and 7b). 
Furthermore, exposure of OVCAR3 and FUOV1 cells to 
carboplatin and paclitaxel caused a moderate increase in 
PSIP1 levels consistent with PSIP1 being responsive to 
cellular stress, and in the case of carboplatin, potentially 
responsive to DNA damage (Supplementary Figure 
13c). In long-term cell viability assays we also found 
that depletion of PSIP1 itself has significant effect on 
cell viability (Figure 7c) of ovarian cancer cell lines 
suggesting some level of dependency on PSIP1 levels for 
cell survival.
DISCUSSION
We have carried out the first GWAS of PFS in 
European women diagnosed with EOC. We identified two 
SNPs in strong linkage disequilibrium (LD) in an intron of 
the TTC39B gene that were associated with worse PFS in 
patients with serous EOC. PFS in patients carrying the rare 
allele of rs7874043 is ~5 months shorter than in patients 
carrying the common allele. In particular for patients with 
high-grade serous EOC at advanced stage who often have 
poor survival, the SNP is also associated with ~4 months 
difference in PFS. Despite the large differences in PFS, 
these associations did not reach genome-wide significance 
(P < 5x10-8). We estimate that to reach genome-wide 
significance for the allele frequency of rs7874043, 
we would need twice as many serous EOC patients, 
depending on the true HR, with germline DNA samples 
and detailed clinical follow up data. We found attenuated 
associations with PFS in ovarian cancer patients who were 
selected with no regard to chemotherapy, reflecting either 
chance variation or that the effects of this SNP are specific 
to the treatment response. Furthermore, we found these 
SNPs had a significant, albeit weaker association with OS.
We have shown that the regulatory element, 
in which rs7874043 and rs72700653 lies, acts as a 
transcriptional enhancer on the PSIP1 and CCDC171 
promoters, and that haplotype carrying the minor alleles 
of these SNPs enhances expression of the non-canonical 
TTC39B promoter. All three genes are located at 9p22.3, 
a region of chromosomal gain previously identified by 
comparative genomic hybridization in ovarian tumors as 
being associated with resistance to paclitaxel/carboplatin 
Figure 7: PSIP1 inhibition impaired DNA damage-induced homologous recombination function in ovarian cancer 
cell lines. A. Representative images of the OVCAR3 cell line transfected either with nontargeting scramble control (siCON) or PSIP1 
(siPSIP1) RNAi for 48h, irradiated (IR) with 6 Gy and immunostained with anti-RAD51 (red) and DAPI (blue). B. Quantification of 
RAD51 positive foci after PSIP1 depletion alone and with 6 Gy IR. The percentage of cells with  > 10 RAD51 foci were calculated. Error 
bars denote SEM (N  =  2 with more than 50 cells were counted for each experiment). C. Effect of PSIP1 silencing on long-term colony 
formation in OVCAR3 and FUOV1 determined using crystal violet staining. P values were determined with a two-tailed t test. **p  < 
0.01,***p  <  0.001.
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therapy [28]. The best characterized of the affected genes 
is PSIP1 (PC4 And SFRS1 Interacting Protein 1), also 
known as LEDGF (Lens Epithelial Derived Growth 
Factor), which is a epigenetic reader recognizing H3K36 
marks that preferentially associate with the internal coding 
areas of actively transcribed genes [29, 30]. PSIP1 is 
known to have oncogenic activity that controls a caspase-
independent lysosomal cell death pathway [31], and can 
protect against cell death induced by many different 
stimuli including etopside, anthracyclines, docetaxel 
and oxidative stress [32]. PSIP1 is overexpressed in 
chemoresistant acute myelogenic leukemia and protects 
leukemic cells from apoptosis in vitro [33]. PSIP1 is 
thought to protect cells from stress-induced apoptosis 
by transcriptionally activating protective genes such 
as HSP27 and CRYAB (alphaB-crystallin) [34]. More 
recently, PSIP1/LEDGF has been shown to regulate 
homologous recombination DNA repair pathway by 
guiding the tethering of Retinoblastoma binding protein 
8 (RBBP8; also known as CtBP-Interacting Protein) 
to specific areas of chromatin (H3K36me3) in a DNA 
damage-dependent manner, providing a mechanism for 
its ability to protect cancer cells from DNA damage [35]. 
PSIP1 is also involved in HIV integration and is therefore 
a promising candidate for anti-retroviral therapy [36, 37]. 
Almost nothing is known about the function of 
CCDC171 (Coiled-Coil Domain Containing 171) except 
that it has been identified as an NRF1 target gene based 
on a Chip-Seq screen [38]. NRF1 plays a crucial role 
in maintenance of mitochondrial function and oxidative 
stress response. TTC39B (c9orf52) encodes a potential 
transmembrane protein and two GWAS for lipid levels 
have identified common SNPs in this locus associated 
with high density lipoprotein cholesterol (HDL-C) levels 
[39, 40]. This association was confirmed in a mouse model 
which showed that knockdown of TTC39B resulted in 
elevated levels of HDL-C [39]. These common SNPs are 
not strongly correlated with the rare SNPs we found to be 
associated with PFS (r2 < 0.1), and it is unknown whether 
they regulate the expression of the same novel TTC39B 
isoform that we identified. We cannot predict the function 
of this novel isoform but we have shown that it is not 
expressed at detectable levels in most ovarian cell lines, 
nor in approximately one-third of serous ovarian tumors.
Our data implicate Sp1 as a potential mediator 
of target gene(s) expression. Sp1 binds GC-rich DNA 
elements and regulates target genes by recruiting and 
complexing with transcription-associated proteins to 
activate or repress gene expression [41]. Notably, Sp1 is 
also able to mediate long-range activation of transcription 
through chromatin looping [30], and the PSIP1 promoter 
CpG island contains Sp1-responsive sites [42]. We showed 
the minor C allele of rs7874043 preferentially binds Sp1 
in vitro, and that Sp1 binds to a region encompassing 
rs7874043, in vivo. Consistent with the known function of 
Sp1 in chromatin looping, we showed that Sp1 silencing 
ablated chromatin looping with the PSIP1 promoter and 
reduced PSIP1 expression. We therefore suggest that the 
minor allele of rs7874043 enhances chromatin looping 
between the PRE and the PSIP1 promoter to increase 
PSIP1 expression. Unfortunately, we were unable to 
identify any heterozygous cell lines for rs7874043, and 
therefore confirmation of these findings by evaluation of 
additional allele-specific effects was not possible in this 
study. 
Although the absolute differences in PFS for 
carriers of the rare TTC39B alleles, compared to the 
common alleles, are quite large, the alleles are too rare 
to be responsible for much of the observed variation in 
PFS between affected women. Amongst the strengths 
of our study is the inclusion of only cases who had 
received standard first line treatment with carboplatin 
and paclitaxel, and the focus on clinically measurable 
PFS following first-line treatment, rather than on OS 
following exposure to multiple different drugs. Although 
we were able to obtain sufficient data in the population-
based OCAC sites to conduct this study, it is much easier 
to do these studies in the context of clinical trials. Our 
study therefore emphasizes the importance of collecting 
germline DNA in clinical trials, and using them to detect 
biomarkers of response.
In conclusion, through a GWAS we have identified 
a SNP, rs7874043, as a very strong candidate for having 
a direct causal effect on PFS in ovarian cancer patients 
following first-line chemotherapy. We provide evidence 
that this SNP falls within a distal regulatory element that 
regulates several genes, including PSIP1, and show that 
high expression of PSIP1 is associated with poor PFS 
in ovarian cancer patients. We observed a significant 
reduction in cell viability following PSIP1 inhibition, 
suggesting that PSIP1 is a potential target for therapeutic 
intervention in ovarian cancer as previously suggested 
for other cancers [31]. Moreover, like other cancer cell 
lines, transient silencing of PSIP1 in an ovarian cancer 
cell line significantly impaired DNA damage-induced 
RAD51 foci formation suggesting involvement of PSIP1 
in the regulation of homologous recombination-mediated 
DNA repair. PSIP1 is involved in HIV integration, and 
so there is already some interest in developing specific 
inhibitors. Successful inhibition of PSIP1 may provide a 
novel approach to target ovarian cancer.
MATERIALS AND METHODS
Patient selection criteria
All participating studies received approval from 
the respective Institutional Ethics Boards. In order to 
study a homogeneous group of patients in Phase 1, 
we selected patients from AOCS, MAYO and TCGA 
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based on the following criteria: the primary cancer sites 
described as ovarian, fallopian tube or primary peritoneal, 
invasive serous histology, collection of primary treatment 
response data completed at the time of patient selection, 
high grade (grade 2 or 3), FIGO stage III or IV. Similar 
patient selection criteria were applied to OCAC studies 
in the following phases, except that the patients with low 
grade and low stage were also included. To improve cost 
efficiency, we preferentially genotyped AOCS patients 
with extreme phenotypes in Phase 1 (Supplementary 
Methods).
We observed substantial heterogeneity among 
treatments that patients in OCAC received, with more 
than 80 different chemotherapy drug combinations, dosage 
levels and schedules used for first-line chemotherapy, 
so we further selected patients who were treated with 
only three weekly paclitaxel and carboplatin as first-line 
therapy. Among these patients, the majority received  > 
4 cycles of paclitaxel at a dose of 135 to 175 mg/m2 and 
carboplatin at AUC 5 to 7), while dosage for some patients 
was unknown. 
Prior to commencing data analysis in Phase 2, we 
obtained updated clinical data, which revealed that 91 
AOCS and MAYO patients included in Phase 1 no longer 
met the criteria we applied because they had received 
agents in addition to carboplatin/paclitaxel, or  < 4 cycles 
of paclitaxel and carboplatin. Other data updates on 
residual disease and other clinical features meant that an 
additional 15 cases were no longer eligible for the analysis. 
We therefore excluded these cases from further analyses. 
All the following analyses were based on the most up-to-
date clinical data. To summarize, we analyzed a total of 
1244 cases who had received standard chemotherapy plus 
an additional 1346 cases who had received non-standard 
chemotherapy for the analyses selected with no regard to 
chemotherapy. The details of their treatment is provided in 
the Supplementary Table 5.
Genotyping and imputation
AOCS, MAYO and TCGA patients were genotyped 
using Illumina HumanOmni1-Quad arrays, HumanHap 
610 arrays and Human1M arrays, respectively. We applied 
the following quality control steps for all three sets of 
GWAS data separately: 1) removing samples with  > 10% 
missing genotypes; 2) excluding any SNP with less than 
1% minor allele frequency (MAF); 3) excluding any SNP 
that failed the Hardy-Weinberg Equilibrium (HWE) test at 
the significance level of 5e-6; 4) excluding the SNPs with 
MAF  > 5% when per SNP no-call rate  >  5%, and those 
with MAF  < 5% when per SNP no-call rate  > 1%. We 
then assessed the cryptic relationship between the sample 
pairs using the ‘—genome’ command in PLINK [43]. The 
proportion of identical by descent (IBD) was estimated 
from the cleaned whole genome data, and then either 
of the paired IDs showing high levels of IBD sharing 
(PI_HAT > 0.2) was dropped. Patients who have been 
recruited in both MAYO and TCGA were identified using 
this approach and were included in the analyses only once. 
Following the check of cryptic relationships, we assessed 
potential population stratification using a Principal 
Components Analysis (PCA) algorithm EIGENSTRAT 
[44]. The HapMap 3 and GenomeEUTwin [45] individuals 
were used as a reference panel in the calculation of the 
principal components, and the current samples were 
projected into the background of reference population. We 
used 6 standard deviations (SDs) as the cut-off to identify 
ancestral outliers, which were removed from further 
association analysis. After these data cleaning, 183 AOCS 
patients (766,728 SNPs) and combined 68 MAYO and 134 
TCGA patients (525,792 SNPs) were included in Phase 1 
analysis.
To improve array comparison, we inferred the 
missing genotypes for the initial GWAS samples with the 
reference of the CEU samples from the 1000 Genomes 
pilot 1 data (June, 2010 release) using MACH 1.0 [23]. 
We had 385 samples on a common set of 297,906 SNPs 
without strand ambiguity (i.e. A|T or C|G genotypes) for 
imputation. We have imputed up to 6.86 million SNPs, 
with 88.7% (~6 million) SNPs obtaining reasonable 
imputation quality (imputed R2 > 0.3). 
We used the Sequenom MassARRAY iPLEX 
platform for genotyping in Phase 2-4, using previously 
described methods and quality control measures [46]. ‘Tag 
SNP Picker’ option at the HapMap web site was used to 
pick 45 SNPs which captured 187 TTC39B variants (MAF 
>  5%, in r2 > 0.5 with tag SNPs) from HapMap CEU 
set. 40 SNPs among this tag-SNP list were successfully 
genotyped and passed QC.
Progression-free survival and overall survival
PFS was defined as the time interval between the 
date of histologic diagnosis and the first confirmed sign 
of disease recurrence, or progression (Supplementary 
Table 3). As a related survival trait, OS was defined as 
the time interval from date of diagnosis to time of last 
follow-up or time to death from any cause. To control for 
ascertainment bias, prevalent cases (with an interval  > 
12 months between the date of histological diagnosis and 
DNA collection) were excluded from analysis. There were 
a small number of cases who died without any reported 
evidence of progression (N = 17), and for them we applied 
right censoring to PFS at the time of last assessment. 
Statistical analysis
The allelic association with PFS or OS was assessed 
in a Cox Proportional Hazards (CPH) model, adjusting 
for potential site differences and prognostic factors of 
grade (low vs high), stage (4 levels), residual disease (nil 
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vs any) and age of diagnosis (specific to the analysis of 
OS). We tested the proportional hazards assumption for 
the adjusted variables and stratified by those that violated 
the assumption. In most analyses, we found that study site 
was the major variable violating the assumption; therefore, 
we fitted sites as strata in the model. By fitting strata, we 
assumed that there were baseline level differences in PFS 
between the patients from different sites but no difference 
in the hazard ratio conferred by the SNP being tested.
The data from Phase 1 MAYO and TCGA sets were 
combined for analysis while stratifying for site differences, 
because, unlike those from AOCS, they were not selected 
for extreme phenotypes. To increase the statistical power 
in Phase 1, we performed a meta-analysis of the results 
from the AOCS and the combined MAYO and TCGA 
set using an inverse-variance weighting approach. When 
performing pooled analyses in Phase 2-4, we pooled data 
from all studies while stratifying by study sites. 
Cell lines
Human ovarian carcinoma cell lines A2780, JAM, 
OVCAR3 and FUOV1 were grown either in RPMI 
medium or DMEM/F12 with 10-20% FCS and antibiotics. 
Cell lines were maintained under standard conditions, 
routinely tested for Mycoplasma and identity profiled with 
short tandem repeat markers. 
Electrophoretic mobility shift assays (EMSAs)
EMSAs were carried out as previously described 
[47], except that oligonucleotides were detected using 
a Chemiluminescent Nucleic Acid Detection Module 
kit (Cat no 89880, Thermo Scientific). Oligonucleotide 
sequences used in the assays are listed in Supplementary 
Table 6. Competitor oligonucleotides were used at 30-fold 
molar excess.
In silico prediction of transcription factor binding 
sites
Prediction of transcription factor binding sites was 
performed using the AliBaba 2.1 program (http://www.
generegulation.com/pub/programs/alibaba2/index.html) 
[24].
Chromatin immunoprecipitation (ChIP) qPCR
Sp1 ChIP-qPCR (Sp1; D4C3 rabbit monoclonal, 
Cell Signalling) assays were conducted as described 
previously [48] with a sheared fragment size of 300 bp to 
1 kb. For qPCR, 1 µl from 30 µl of DNA extract was used. 
Primers are listed in Supplementary Table 6.
Chromatin conformation capture (3C)
3C libraries were generated using HindIII, EcoRI 
or BglII as described previously [49]. 3C interactions 
were quantitated by real-time PCR (qPCR) using primers 
designed within restriction fragments (Supplementary 
Table 6). All qPCRs were performed on a RotorGene 
6000 using MyTaq HS DNA polymerase with the addition 
of 5 mM of Syto9, annealing temperature of 66oC and 
extension of 30sec. 3C analyses were performed in three 
independent experiments with each experiment quantified 
in duplicate. BAC clones (RP11-746M21, RP11-940C5, 
RP11-356J15, RP11-728G24) covering the 9p22 region 
were used to create artificial libraries of ligation products 
in order to normalize for PCR efficiency. Data were 
normalized to the signal from the BAC clone library 
and, between cell lines, by reference to a region within 
GAPDH. All qPCR products were electrophoresed on 2% 
agarose gels, gel purified and sequenced to verify the 3C 
product. 
Plasmid construction and luciferase assays
The TTC39B, PSIP1 and CCDC171 promoter-
driven luciferase reporter constructs were generated by 
inserting PCR-generated promoter fragments into the 
multiple cloning site (MCS) of pGL3-Basic. A 2.2 kb 
fragment containing the PRE was inserted into the BamHI 
and SalI sites downstream of luciferase. The minor 
alleles of rs72700653 and rs7874043 were introduced 
into promoter and PRE constructs by overlap extension 
PCR. All constructs were sequenced to confirm variant 
incorporation (AGRF, Australia). Primers used to 
generate all constructs are listed in Supplementary Table 
6. A2780 and JAM ovarian cancer cells were transfected 
with equimolar amounts of luciferase reporter plasmids 
and 50ng of pRLTK using Lipofectamine 2000. The 
total amount of transfected DNA was kept constant per 
experiment by adding carrier plasmid (pUC19). Luciferase 
activity was measured 24 hours post-transfection using the 
Dual-Glo Luciferase Assay System on a Beckman-Coulter 
DTX-880 plate reader. To correct for any differences in 
transfection efficiency or cell lysate preparation, Firefly 
luciferase activity was normalized to Renilla luciferase. 
The activity of each test construct was calculated 
relative to promoter constructs, the activity of which was 
arbitrarily defined as 1. 
siRNA silencing
Sp1 (L-026959-00) and non-targeting (D-001810-
10-20) ON-TARGETplus SMARTpool, PSIP1 (J-015209-
05-0005 and J-015209-06-0005) and non-targeting 
(D-001810-01-05) siRNAs for were purchased from 
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Thermo Scientific. For siRNA silencing, JAM cells were 
transfected with 25 nM of either Sp1 or non-targeting 
siRNAs using Lipofectamine 2000 and lysates prepared 
for 3C after 48 hours. 
Taqman expression assays
JAM total RNA was extracted using Trizol (Life 
Technologies). Residual DNA contaminants were removed 
by DNAse treatment (Ambion) and complementary 
DNA was synthesized using random primers as per 
manufacturers’ instructions (Life Technologies). All 
qPCRs were performed on a RotorGene 6000 (Corbett 
Research) with TaqMan Gene Expression assays 
(Hs01045711_g1 for Sp1, Hs00916521_m1 for PSIP1 and 
Hs00411735_m1 for  CCDC171) and TaqMan Universal 
PCR master mix. All reactions were normalized against 
β-glucuronidase (Catalogue No. 4326320E). 
RAD51 foci formation
OVCAR3 cells were reverse transfected with 10nM 
of siRNAs targeting PSIP1 (siPSIP1) described above for 
24 h and later seeded on the 0.1% poly-l-lysine coated 
coverslips followed by second reverse transfection for 
additional 24 h. To determine RAD51 foci accumulation, 
cells were irradiated (IR) with 6 Gy (137Cesium) and 
analyzed 6 h after irradiation as described previously [50].
Colony formation assays
48 h after siRNA transfection, 10,000-20,000 cells 
were seeded in 24 well plates and incubated for additional 
7 days to determine colony viability. The colonies were 
fixed with 0.05% crystal violet for 30 minutes, washed 
and quantified for crystal violet intensity after destaining 
using Sorenson’s buffer (0.1 M sodium citrate in 50% 
Ethanol, pH 4.2) at 590 nM absorbance using PowerWave 
HT Microplate Spectrophotometer (BioTeK, USA).
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